EGFR-mutated non-small cell lung cancer

Activating mutations in the epidermal growth factor receptor (EGFR) gene drive about 15% of the cases of non-small cell lung cancer (NSCLC) in non-Asian populations and up to 50% in Asian populations.1 Although tyrosine kinase inhibitors targeting these mutations are initially highly effective, most patients with advanced disease eventually experience cancer progression owing to the development of drug resistance.2 The current treatment options for resistance to tyrosine kinase inhibitors are limited. Most patients receive standard chemotherapy, with limited efficacy and substantial toxicity.3 In a linked study (doi:10.1136/bmj-2025-085680), Fang and colleagues addressed this critical clinical challenge by showing that sacituzumab tirumotecan, a novel antibody-drug conjugate targeting trophoblast cell surface antigen 2, showed remarkable efficacy in Chinese patients with EGFR-mutated NSCLC with disease progression after treatment with both tyrosine kinase inhibitors and platinum based chemotherapy.

Trophoblast cell surface antigen 2 is a protein overexpressed in many NSCLC tumors, particularly those with EGFR-activating mutations, making it an attractive target for the development of antibody-drug conjugates, which combine targeted antibodies with potent chemotherapy drugs.45 Previous trophoblast cell surface antigen 2 directed antibody-drug conjugates showed early promise but failed to demonstrate clinically meaningful survival benefits in unselected populations with NSCLC in phase 3 trials.56 Sacituzumab tirumotecan is a novel trophoblast cell surface antigen 2 directed antibody-drug conjugate, engineered with an enhanced drug delivery system to improve stability and bioactivity.7 Post hoc analyses from earlier trials showed that patients with EGFR-mutated tumors responded favorably to this drug, likely due to increased expression of trophoblast cell surface antigen 2 and enhanced cellular uptake.8 These findings were further strengthened by the positive results from a non-randomized trial in 64 previously treated patients with EGFR-mutated NSCLC that provided compelling rationale for testing sacituzumab tirumotecan in a randomized trial specifically designed for this patient population.8

In their study, Fang and colleagues reported the results of such a trial conducted in China. In this multicenter, open label, randomized controlled, the investigators enrolled 137 patients with EGFR-mutated NSCLC with disease progression after treatment with tyrosine kinase inhibitors and subsequent platinum based chemotherapy. Patients were randomized 2:1 to receive either sacituzumab tirumotecan or docetaxel as standard of care. The results were striking: 45% of patients responded to sacituzumab tirumotecan compared with only 16% with docetaxel; median progression-free survival was more than doubled (6.9 v 2.8 months), and the 12 month overall survival rate was also higher (73% v 54%). Importantly, the safety profile appears manageable, with fewer grade-3 or higher adverse effects compared with docetaxel (56% v 72%) and no patient discontinued treatment due to adverse effects. Clinical benefit was observed across multiple patient subgroups, with notable response rates even among patients with medium to low baseline expression of trophoblast cell surface antigen 2, potentially supporting broader clinical use.

This study is the first randomized trial demonstrating that a trophoblast cell surface antigen 2 directed antibody-drug conjugate can deliver statistically significant and clinically meaningful improvements in patients with EGFR-mutated NSCLC, leading to approval in China.9 However, several limitations affect broader application. The study used tumor shrinkage rather than patient survival as the primary endpoint, which limited interpretation of long term benefit.1011 The trial was conducted exclusively in Chinese patients, so findings may not apply to other populations with different genetic backgrounds.12 Additionally, data on patient quality of life—an increasingly important measure of treatment benefit—were limited.13 Given these constraints and the lack of established clinical guidelines, clinicians outside China should await results from ongoing international phase 3 trials141516 before incorporating sacituzumab tirumotecan into routine practice.

The promise of sacituzumab tirumotecan exemplifies the power of precision medicine, showing how targeting a disease molecular subtype can yield substantial clinical benefits. However, several important questions remain that will shape future clinical guidelines and practice. For immediate clinical implementation, guidelines for patient selection criteria, optimal treatment sequences, and management strategies for patients when sacituzumab tirumotecan stops working need to be developed. This includes identifying biomarkers beyond expression levels of trophoblast cell surface antigen 2 that could predict treatment responsiveness, given that not all patients respond. From a research perspective, investigators should explore the underlying mechanisms of primary and acquired resistance, which could lead to more effective treatment strategies. Future clinical trials should evaluate combination strategies, including integration with EGFR tyrosine kinase inhibitors as first line treatment or with immune checkpoint inhibitors to enhance efficacy. Parallel studies are needed to optimize dosing regimens and formulations to improve potency while reducing adverse effects.

These promising results offer renewed hope for patients with advanced EGFR-mutated NSCLC and provide a foundation for future innovation in the treatment of this challenging disease. As we anticipate this important milestone—the potential for sacituzumab tirumotecan to transform treatment for patients with EGFR-mutated NSCLC—we must continue to harness the power of precision medicine to deliver better treatments to patients worldwide.